[Use of monoclonal antibodies for the immuno-imaging of cancers].
Monoclonal antibodies are expected to carry radio-nuclides selectively to cancer tissues and to offer antigen-specific diagnosis and/or therapy of cancer. Monoclonal antibodies tagged with indium (111In) and technetium (99mTc) are clinically used for the localization of malignant melanoma, colorectal and ovarian cancer. They have detected about 80% of tumors, tumors missed by conventional diagnostic methods and tumors in patients with normal serum tumor marker levels. Acute or subacute toxicity was not observed. However, human anti-murine antibodies (HAMA) were detectable in sera of some cases after receiving radiolabeled monoclonal antibodies. Development of protein engineering has made it possible to produce humanized antibodies, which are expected to diminish the HAMA response. The same monoclonal antibodies are also employed for therapy of some cancers using iodine (131I), yttrium (90Y) and rhenium (186Re) labeled antibodies.
Endo
K
K
Dept. of Nuclear Medicine, Gunma University School of Medicine.
Oriuchi
N
N
Takenoshita
S
S
D000818:Animals; D000911:Antibodies, Monoclonal; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging*; D005260:Female; D006801:Humans; D007205:Indium Radioisotopes; D008297:Male; D008545:Melanoma / Q000000981:diagnostic imaging; D051379:Mice; D008875:Middle Aged; D011877:Radionuclide Imaging; D013667:Technetium
D000911:Antibodies, Monoclonal; D007205:Indium Radioisotopes; D013667:Technetium